Smac mimetics: implications for enhancement of targeted therapies in leukemia (Q33683159)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Smac mimetics: implications for enhancement of targeted therapies in leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

E Weisberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

A Ray

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

R Barrett

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

E Nelson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

A L Christie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

D Porter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

C Straub

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

L Zawel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

J F Daley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

S Lazo-Kallanian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

R Stone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

I Galinsky

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

D Frank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

J D Griffin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

16 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

2100-2109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

XIAP is not required for human tumor cell survival in the absence of an exogenous death signal

14 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Cytoprotective effects of IAPs revealed by a small molecule antagonist

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

The role of FLT3 in haematopoietic malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Bcr-Abl inhibition as a modality of CML therapeutics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Structural basis of IAP recognition by Smac/DIABLO

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

The molecular biology of chronic myeloid leukemia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2010.212

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2010.212

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FLEU.2010.212

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037865

30 October 2018

Identifiers

DOI

10.1038/LEU.2010.212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

14 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

PubMed publication ID

20844561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20844561%20AND%20SRC:MED&resulttype=core&format=json